...
机译:JCAR014与Durvalumab联合治疗复发/难治性侵袭性B细胞非霍奇金淋巴瘤患者的疗效和毒性
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Univ Washington Dept Lab Med Seattle WA 98195 USA;
Univ Washington Dept Lab Med Seattle WA 98195 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
机译:JCAR014与Durvalumab联合治疗复发/难治性侵袭性B细胞非霍奇金淋巴瘤患者的疗效和毒性
机译:匹克酮治疗成人复发或难治性侵袭性非霍奇金B细胞淋巴瘤
机译:欧洲药品管理局对匹克酮的治疗,用于治疗成年复发性或难治性侵袭性非霍奇金氏B细胞淋巴瘤成年患者:人类用药品委员会的科学评估摘要
机译:弥漫性大B细胞淋巴瘤与中枢神经系统复发的突变特征:用于癌症基因组学数据库的CBioPortal分析
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:匹克酮治疗成人复发或难治性侵袭性非霍奇金B细胞淋巴瘤
机译:第1B期研究,以评估Durvalumab与Tremelimumab或Danvatirsen在复发或难治性弥漫性大B细胞淋巴瘤患者中的组合的安全性和有效性